🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)

RecruitingNAAges 18 Years - anyAllIHU Strasbourg
NCT06666803 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Pancreatic ductal adenocarcinoma (PDAC) has the poorest prognosis of all digestive cancers due to lack of early diagnosis and limited response to treatment. Patient-derived organoid technology has become a mainstay of precision oncology, enabling personalised functional characterisation of tumours (e.g. treatment evaluation and drug screening). Initial research carried out as part of the Cancer Profile project has produced the first organoids from resected PDAC parts. Only 15-20% of patients can benefit from surgical resection, which remains the only curative treatment. In contrast, most patients with PDAC undergo diagnostic fine-needle biopsies (FNB) using an echo-endoscopic procedure (EUS). The next step is therefore the reliable generation of organoids from limited quantities of biopsy material obtained by 'EUS-FNB'. The aim of the study presented here is to validate these organoids

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patient over 18 years of age. * Patient undergoing echo-endoscopy with certainty/suspicion of fine needle biopsy (EUS-FNB). * Suspicion of pancreatic lesion * Patient able to receive and understand information relating to the research protocol and to give consent. * Patient affiliated to the French social security system. Exclusion Criteria: * Patient not programmed for endoscopy with certainty/suspicion of fine needle biopsy (EUS-FNB). * Patient undergoing echo-endoscopy and presenting a high risk that may prevent EUS-FNB. * Patient with degenerated Intraductal papillary mucinous neoplasm (IPMN) * Patient with acute pancreatitis within 4 weeks prior to EUS * Pregnant or breast-feeding patient * Patient under court protection. * Patient under guardianship or curatorship. * Patient in a situation of social vulnerability. * Patient under legal protection or unable to express his/her opposition.
💊

What it tests

  • FNB sampling
  • blood sampling
📍

Where

2 sites
Centre d'Endoscopie Digestive
Strasbourg, France
Department of hepato-gastroenterology
Strasbourg, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy